InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,105.19
(
-0.21%
)
US TECH 100
17,243.20
(
-0.39%
)
Dow Jones
38,258.05
(
-0.33%
)
Brent Oil
85.91
(
-1.58%
)
Bitcoin
61,339.63
(
-3.92%
)
Post# of 251649
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119514
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: masterlongevity post# 139260

Wednesday, 06/06/2012 11:30:42 AM

Wednesday, June 06, 2012 11:30:42 AM

Post# of 251649
Update on Gantenerumab for early AD:

http://finance.yahoo.com/news/morphosys-antibody-reaches-major-milestone-055200700.html

MorphoSys AG announced today that its partner Roche has expanded the ongoing SCarlet RoAD Phase 2 clinical trial of gantenerumab for prodromal (early) Alzheimer's disease to a potentially pivotal study. The trial size will be increased from 360 to 770 participants, and a favorable outcome to the trial could be used by Roche to support a marketing application for gantenerumab.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up